Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Home
report store
pulmonary arterial hypertension pah market insight

SALE

Pulmonary Arterial Hypertension (PAH) Market Insight, Epidemiology and Market Forecast -2030

Published Date : 2021

Pages : 183

Region : United States, Japan, EU4 & UK

SALE

Summary
TOC Table of Content
LOT
Companies
- Sample Request

pulmonary arterial hypertension pah market insight

DelveInsight’s ‘Pulmonary Arterial Hypertension (PAH)–Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Pulmonary Arterial Hypertension, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Pulmonary Arterial Hypertension (PAH) market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted PAH symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Pulmonary Arterial Hypertension (PAH) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geographies Covered

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2018–2030

Pulmonary Arterial Hypertension (PAH) Disease Understanding and Treatment Algorithm

Pulmonary Arterial Hypertension (PAH) Overview

Pulmonary Arterial Hypertension (PAH) is a progressive disease of the lung vascular system, primarily affecting the small pulmonary arterioles. PH is defined as mean pulmonary artery pressure greater than 25 mm Hg measured during right heart catheterization. The term PAH describes a subset of patients who also have the presence of pre-capillary hypertension, including an end-expiratory pulmonary artery wedge pressure (less than 15 mm Hg) and a pulmonary vascular resistance greater than 3 Woods units. PAH has three subgroups: idiopathic, heritable, and pulmonary arterial hypertension related to risk factors or associated conditions.

Elevated pulmonary vascular resistance is caused by the proliferation of endothelial and smooth muscle cells, causing tunica media hypertrophy of small-caliber pulmonary arteries. Moreover, the endothelial cells have impaired the production of nitric oxide and prostacyclin. Patients with idiopathic and heritable forms of pulmonary artery hypertension (HPAH) are distinguished by identifying an inheritable genetic mutation; whereas, idiopathic forms have an underlying genetic predisposition to develop pulmonary hypertension. Regardless, both forms have genetic mutations that overlap each disease process.

PAH is most-commonly idiopathic and is characterized by increased vascular resistance and blood vessel narrowing within the pulmonary vasculature. Restricted flow through pulmonary arteries, as found in PAH, is thought to have molecular and genetic causes which lead to hypertrophy of smooth muscle, endothelial cells, and adventitia. In response to the increased resistance, the right ventricle will increase filling and stroke volume, increasing pulmonary arterial pressure. Over time, right ventricular hypertrophy develops. In the other groups of PH, increased pulmonary vascular resistance is similarly due to restricted flow, but it is typically secondary to another process such as left heart disease, chronic lung disease or chronic pulmonary thromboembolism.

The cardinal symptom of every form of pulmonary hypertension is progressive exercise dyspnea, often accompanied by fatigue and exhaustion. The symptoms are unspecific, so there is often a delay of many months or even years between the onset of symptoms and diagnosis. With the progression of the disease the symptoms become worse and new symptoms occur, e.g., dyspnea on bending down (bendopnea) and syncope, the latter particularly during or immediately after physical exertion. In patients with pulmonary hypertension, frequent syncope even on slight exertion clearly points to the presence of a life-threatening state associated with high mortality. In the event of cardiac decompensation the right cardiac filling pressures rise, with the typical triad of cervical venous congestion, ascites, and edema. The most frequently occurring signs, often subtle, are peripheral or central cyanosis (often only, or more strongly, during exercise), a pronounced pulmonary valve component of the second heart sound, and a systolic flow murmur reaching its maximum at a left parasternal location in tricuspid valve insufficiency.

Early detection and precise classification of the disease are the essential goals of diagnosis in pulmonary hypertension. With physical examination, the basic diagnostic tests in every case of uncertain or progressive exercise dyspnea should include ECG and determination of brain natriuretic peptide (BNP) or the N-terminal fragment of its precursor (NT-proBNP). If both of these show no abnormality, pulmonary hypertension is highly unlikely to be present. Further diagnostic investigations are required only in the case of strong clinical suspicion of pulmonary hypertension or if the results of the tests mentioned above are unclear. Pathologic ECG or BNP findings unequivocally indicate further cardiological investigation.

Treatment of PAH has progressed significantly over the past few decades in both its complexity and efficacy. The therapy aims to achieve a low-risk status (maintaining WHO-FC II if possible) to preserve patient function, quality of life and minimize mortality risk. This is generally achieved by optimizing the patient’s 6 minute walk distance (6MWD); however, current target thresholds rely upon cohort studies and expert consensus.

PAH management involves a stepwise pragmatic approach from general supportive treatment up to targeted pharmacological interventions. Selected patients undergo vasoreactivity testing, with those that exhibit sufficient vasodilation subsequently being commenced on regular high-dose calcium channel blockers (CCB). Patients who either fail to qualify for vasoreactivity testing or demonstrate inadequate response are then commenced on targeted monotherapy or combination therapies that counteract the pathophysiology of the condition.

Pulmonary Arterial Hypertension (PAH) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Pulmonary Arterial Hypertension (PAH) market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The DelveInsight Pulmonary Arterial Hypertension (PAH) market report gives a thorough understanding of PAH symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides PAH treatment algorithms and treatment guidelines in the US, Europe, and Japan.

Pulmonary Arterial Hypertension (PAH) Epidemiology

The epidemiology division’s Pulmonary Arterial Hypertension (PAH) symptoms provide insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Pulmonary Arterial Hypertension (PAH) epidemiology segmented as the Total Prevalent Cases of Pulmonary Arterial Hypertension (PAH), Sub-type Specific Prevalent cases of PAH, Gender Specific Prevalence of PAH. The report includes the prevalent PAH scenario in 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Pulmonary Arterial Hypertension (PAH) Epidemiology

The epidemiology segment also provides the Pulmonary Arterial Hypertension (PAH) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total 7MM prevalent cases of Pulmonary Arterial Hypertension (PAH) were 71,816 in 2020.

Pulmonary Arterial Hypertension (PAH) Drug Chapters

The drug chapter segment of the Pulmonary Arterial Hypertension (PAH) report encloses the detailed analysis of PAH marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Pulmonary Arterial Hypertension clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Chemotherapy or immunotherapy may be warranted postoperatively, depending on cancer staging and nodal involvement. The surgical nurse practitioner, a member of the medical oncology team, can coordinate the surveillance plan of care and review laboratory results.

Products detail in the report…

Pulmonary Arterial Hypertension (PAH) Emerging Drugs

Sildenafil (Revatio): Pfizer

The SUPER-2 extension trial evaluated the long-term safety and tolerability of sildenafil for the treatment of PAH, enrolling 93% of SUPER-1 participants. Each patient enrolled in SUPER-2 was titrated to the maximum tolerable TID dose of sildenafil (up to 80 mg per dose) with 6 min walk assessed at each scheduled visit. At the end of the 3-year study period, 87% of enrollees who remained on treatment received 80 mg of sildenafil TID, while 8% received 40 mg TID, and 5% received 20 mg TID. Overall, 39 (14%) subjects discontinued treatment due to known or perceived sildenafil-related adverse effects, and 59 (22%) died. Of the 277 patients who completed SUPER-1, 31% improved, and 29% maintained their baseline New York Heart Association (NYHA) functional class at a 3-year follow-up (Dodgen & Hill, 2015).

Products detail in the report…

Pulmonary Arterial Hypertension (PAH) Market Outlook

The Pulmonary Arterial Hypertension market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Pulmonary Arterial Hypertension market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

This segment gives a thorough detail of PAH market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Pulmonary Arterial Hypertension (PAH) market in 7MM is expected to change in the study period 2018–2030.

Key Findings

This section includes a glimpse of the Pulmonary Arterial Hypertension market in 7MM. The market size of PAH in the seven major markets was found to be USD 4,777 million in 2020.

The United States Market Outlook

This section provides a total of PAH market size and market size by therapies in the United States.

The United States accounts for the highest PAH market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

EU-5 Countries: Market Outlook

The total Pulmonary Arterial Hypertension (PAH) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Pulmonary Arterial Hypertension (PAH) market size and market size by therapies in Japan are also mentioned.

Pulmonary Arterial Hypertension (PAH) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers Pulmonary Arterial Hypertension (PAH) market uptake by drugs, patient uptake by therapies, and drug sales.

This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake in making financial and regulatory decisions.

Pulmonary Arterial Hypertension (PAH) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Pulmonary Arterial Hypertension (PAH) key players involved in developing targeted therapeutics.

Major players L606 (Pharmaosa Biopharma Inc.), MK5475 (Merck Sharp & Dohme Corp.), Treprostinil Palmitil (Insmed Incorporated), RT234 (Respira Therapeutics) etc being assessed as potential therapies to be available in the market in the coming future.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Pulmonary Arterial Hypertension emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinion working Pulmonary Arterial Hypertension (PAH) domain through primary research to fill the data gaps and validate our secondary research. Their opinions help understand and validate current and emerging therapies treatment patterns or PAH market trends. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Pulmonary Arterial Hypertension (PAH) Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

The report covers the descriptive overview of Pulmonary Arterial Hypertension (PAH) explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
Comprehensive insight has been provided into the Pulmonary Arterial Hypertension (PAH) epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Pulmonary Arterial Hypertension is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Pulmonary Arterial Hypertension (PAH) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies by understanding trends shaping and driving the global Pulmonary Arterial Hypertension (PAH) market

Report Highlights

In the coming years, Pulmonary Arterial Hypertension (PAH) market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence Pulmonary Arterial Hypertension (PAH) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
Major players are involved in developing therapies for PAH. The launch of emerging therapies will significantly impact the Pulmonary Arterial Hypertension market
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for PAH
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Pulmonary Arterial Hypertension (PAH) Report Insights

Patient Population
Therapeutic Approaches
Pulmonary Arterial Hypertension (PAH) Pipeline Analysis
Pulmonary Arterial Hypertension (PAH) Market Size and Trends
Market Opportunities
Impact of upcoming Therapies

Pulmonary Arterial Hypertension (PAH) Report Key Strengths

10 Years Forecast
7MM Coverage
Pulmonary Arterial Hypertension (PAH) Epidemiology Segmentation
Key Cross Competition
Highly Analyzed Market
Drugs Uptake

Pulmonary Arterial Hypertension (PAH) Report Assessment

Current Treatment Practices
Unmet Needs
Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers

Key Questions

Market Insights:

What was the Pulmonary Arterial Hypertension (PAH) Market share (%) distribution in 2020, and how would it look in 2030?
What would be the Pulmonary Arterial Hypertension (PAH) total market Size as well as market Size by therapies across the 7MM during the forecast period (2021–2030)?
What are the market’s key findings across 7MM, and which country will have the largest Pulmonary Arterial Hypertension (PAH) market Size during the forecast period (2021–2030)?
At what CAGR, the Pulmonary Arterial Hypertension (PAH) market is expected to grow by 7MM during the forecast period (2021–2030)?
What would be the Pulmonary Arterial Hypertension (PAH) market outlook across the 7MM during the forecast period (2021–2030)?
What would be the Pulmonary Arterial Hypertension (PAH) market growth till 2030, and what will be the resultant market Size in the year 2030?
How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

What are the disease risk, burden, and unmet needs of Pulmonary Arterial Hypertension (PAH)?
What is the historical Pulmonary Arterial Hypertension (PAH) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of Pulmonary Arterial Hypertension(PAH) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What will be the growth opportunities in the 7MM concerning the patient population about Pulmonary Arterial Hypertension (PAH)?
Out of all 7MM countries, which country would have the highest prevalent Pulmonary Arterial Hypertension (PAH) population during the forecast period (2021–2030)?
At what CAGR is the population expected to grow by 7MM during the forecast period (2021–2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

What are the current options for the treatment of Pulmonary Arterial Hypertension (PAH)?
What are the current treatment guidelines for treating Pulmonary Arterial Hypertension (PAH) in the USA, Europe, and Japan?
What are the Pulmonary Arterial Hypertension (PAH) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
How many companies are developing therapies for the treatment of Pulmonary Arterial Hypertension (PAH)?
How many therapies are developed by each company for the treatment of Pulmonary Arterial Hypertension (PAH)?
How many emerging therapies are in the mid-stage and late development stages to treat Pulmonary Arterial Hypertension (PAH)?
What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pulmonary Arterial Hypertension (PAH) therapies?
What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Pulmonary Arterial Hypertension (PAH) and their status?
What are the key designations that have been granted for the emerging therapies for Pulmonary Arterial Hypertension (PAH)?
What are the global historical and forecasted markets of Pulmonary Arterial Hypertension (PAH)?

Reasons to buy

The report will help in developing business strategies by understanding trends shaping and driving the Pulmonary Arterial Hypertension (PAH) market
To understand the future market competition in the Pulmonary Arterial Hypertension (PAH) market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Pulmonary Arterial Hypertension (PAH) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Pulmonary Arterial Hypertension (PAH) market
To understand the future market competition in the Pulmonary Arterial Hypertension (PAH) market

1. Key Insights

2. Report Introduction

3. Pulmonary Arterial Hypertension Market Overview at a Glance

3.1. Market Share (%) Distribution of Pulmonary Arterial Hypertension (PAH) in 2018

3.2. Market Share (%) Distribution of Pulmonary Arterial Hypertension (PAH) in 2030

4. Executive Summary of Pulmonary Arterial Hypertension

5. Organizations contributing towards Pulmonary Arterial Hypertension

6. Disease Background and Overview

6.1. Introduction

6.2. Signs and Symptoms

6.3. Classification of Pulmonary Arterial Hypertension (PAH)

6.3.1. WHO classification

6.3.2. Functional Classification of Pulmonary Arterial Hypertension

6.4. Etiology

6.5. Risk factors

6.6. Pathophysiology

6.6.1. Nitric Oxide Pathway

6.6.2. Prostacyclin-Thromboxane A2 Pathway

6.6.3. Endothelin-1 Pathway

6.7. Diagnosis

7. Management and Treatment

7.1. Treatment Guidelines

7.1.1. CHEST Guidelines [The United States]

7.1.2. European Society of Cardiology (ESC) and of the European Respiratory Society (ERS) Guidelines

8. Epidemiology and Patient Population

8.1. Key Findings

8.2. 7MM Total Prevalent Patient Population of Pulmonary Arterial Hypertension

8.3. Assumption and Rationale

8.4. The United States

8.4.1. Total Prevalent Patient Population of Pulmonary Arterial Hypertensionin in the United States

8.4.2. Sub-type Specific Prevalence of Pulmonary Arterial Hypertension in the United States

8.4.3. Gender specific Prevalence of Pulmonary Arterial Hypertension in the United States

8.5. EU5

8.5.1. Germany

8.5.1.1. Total Prevalent Patient Population of Pulmonary Arterial Hypertension in Germany

8.5.1.2. Sub-type Specific Prevalence of Pulmonary Arterial in Germany

8.5.1.3. Gender specific Prevalence of Pulmonary Arterial Hypertension in Germany

8.5.2. France

8.5.2.1. Total Prevalent Patient Population of Pulmonary Arterial Hypertension in France

8.5.2.2. Sub-type Specific Prevalence of Pulmonary Arterial in France

8.5.2.3. Gender specific Prevalence of Pulmonary Arterial Hypertensionin France

8.5.3. Italy

8.5.3.1. Total Prevalent Patient Population of Pulmonary Arterial Hypertension in Italy

8.5.3.2. Sub-type Specific Prevalence of Pulmonary Arterial Hypertension in Italy

8.5.3.3. Gender specific Prevalence of Pulmonary Arterial Hypertension in Italy

8.5.4. Spain

8.5.4.1. Total Prevalent Patient Population of Pulmonary Arterial Hypertension in Spain

8.5.4.2. Sub-type Specific Prevalence of Pulmonary Arterial in Spain

8.5.4.3. Gender specific Prevalence of Pulmonary Arterial Hypertension in Spain

8.5.5. United Kingdom

8.5.5.1. Total Prevalent Patient Population of Pulmonary Arterial Hypertension in United Kingdom

8.5.5.2. Sub-type Specific Prevalence of Pulmonary Arterial Hypertension in United Kingdom

8.5.5.3. Gender specific Prevalence of Pulmonary Arterial Hypertension in the United Kingdom

8.6. Japan

8.6.1. Total Prevalent Patient Population of Pulmonary Arterial Hypertension in Japan

8.6.2. Sub-type Specific Prevalence of Pulmonary Arterial Hypertension in Japan

8.6.3. Gender specific Prevalence of Pulmonary Arterial Hypertensionin Japan

9. Patient Journey

10. Case Reports

11. Marketed Therapies

11.1. Sildenafil (Revatio): Pfizer

11.1.1. Drug Description

11.1.2. Other Development Information

11.1.3. Safety and Efficacy

11.1.4. Product Profile

11.2. Tadalafil (Adcirca): Eli Lilly and Company/United Therapeutics Corporation/Gilead Sciences/GSK/ICOS Corporation

11.2.1. Drug Description

11.2.2. Other Development Information

11.2.3. Safety and Efficacy

11.2.4. Product Profile

11.3. Selexipag (Uptravi): Actelion Pharmaceuticals/Nippon Shinyaku

11.3.1. Drug Description

11.3.2. Other Development Information

11.3.3. Safety and Efficacy

11.3.4. Product Profile

11.4. Treprostinil sodium (IV, SC): United Therapeutics Corporation

11.4.1. Drug Description

11.4.2. Other Development Information

11.4.3. Safety and Efficacy

11.4.4. Product Profile

11.5. Tyvaso (Treprostinil Sodium, Inhaled): United Therapeutics Corporation

11.5.1. Drug Description

11.5.2. Other Development Information

11.5.3. Safety and Efficacy

11.5.4. Product Profile

11.6. Adempas (Riociguat): Bayer Group

11.6.1. Drug Description

11.6.2. Other Development Information

11.6.3. Safety and Efficacy

11.6.4. Product Profile

11.7. Ambrisentan: Gilead Sciences/GlaxoSmithKline

11.7.1. Drug Description

11.7.2. Other Development Information

11.7.3. Safety and Efficacy

11.7.4. Product Profile

11.8. Macitentan: Actelion Pharmaceuticals

11.8.1. Drug Description

11.8.2. Other Development Information

11.8.3. Safety and Efficacy

11.8.4. Product Profile

11.9. Tracleer: Actelion Pharmaceuticals

11.9.1. Drug Description

11.9.2. Other Development Information

11.9.3. Safety and Efficacy

11.9.4. Product Profile

11.10. Orenitram (Treprostinil diolamine, oral): United Therapeutics

11.10.1. Drug Description

11.10.2. Other Development Information

11.10.3. Safety and Efficacy

11.10.4. Product Profile

11.11. Ventavis: Co Therix

11.11.1. Drug Description

11.11.2. Other Development Information

11.11.3. Safety and Efficacy

11.11.4. Product Profile

11.12. Veletri (Epoprostenol): Actelion Pharmaceuticals

11.12.1. Drug Description

11.12.2. Other Development Information

11.12.3. Safety and Efficacy

11.12.4. Product Profile

12. Emerging Therapies

12.1. Aurora-GT: United Therapeutics

12.1.1. Drug Descriptions

12.1.2. Other Developmental Activities

12.1.3. Clinical Development

12.1.4. Product Profile

12.2. PB1064 (Pemziviptadil): PhaseBio Pharmaceuticals

12.2.1. Drug Descriptions

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Clinical Trials Information

12.2.5. Product Profile

12.3. Sotatercept: Acceleron Pharma Inc.

12.3.1. Drug Descriptions

12.3.2. Other Developmental Activities

12.3.3. Clinical Development

12.3.4. Clinical Trials Information

12.3.5. Product Profile

12.4. Ralinepag: United Therapeutics

12.4.1. Drug Description

12.4.2. Other Development Information

12.4.3. Clinical Development

12.4.4. Clinical Trials Information

12.4.5. Product Profile

12.5. LIQ-861: Liquida Technologies, Inc.

12.5.1. Drug Description

12.5.2. Other Development Information

12.5.3. Clinical Development

12.5.4. Clinical Trials Information

12.5.5. Product Profile

12.6. Rodatristat Ethyl: Altavant Sciences

12.6.1. Drug Description

12.6.2. Other Development Information

12.6.3. Clinical Development

12.6.4. Clinical Trials Information

12.6.5. Product Profile

12.7. AV-101: Aerovate Therapeutics

12.7.1. Drug Description

12.7.2. Other Development Information

12.7.3. Clinical Development

12.7.4. Clinical Trials Information

12.7.5. Product Profile

12.8. RT234: Respira Therapeutics

12.8.1. Drug Description

12.8.2. Other Development Information

12.8.3. Clinical Development

12.8.4. Clinical Trials Information

12.8.5. Product Profile

12.9. GB002: Gossamer Bio Inc.

12.9.1. Drug Description

12.9.2. Other Development Information

12.9.3. Clinical Development

12.9.4. Clinical Trials Information

12.9.5. Product Profile

12.10. MK5475: Merck Sharp & Dohme Corp.

12.10.1. Drug Description

12.10.2. Clinical Development

12.10.3. Clinical Trials Information

12.10.4. Product Profile

12.11. Treprostinil Palmitil: Insmed Incorporated

12.11.1. Drug Description

12.11.2. Clinical Development

12.11.3. Clinical Trials Information

12.11.4. Product Profile

12.12. L606: Pharmaosa Biopharma Inc.

12.12.1. Drug Description

12.12.2. Clinical Development

12.12.3. Clinical Trials Information

12.12.4. Product Profile

13. Other Therapies: Generics

13.1. Calcium Channel Blockers

13.2. Blood Thinners

13.3. Diuretics

13.4. Digoxin (Lanoxin)

14. Pulmonary Arterial Hypertension: 7 Major Market Analysis

14.1. Key Findings

14.2. Market Size of Pulmonary Arterial Hypertension in 7MM

14.3. Market Size of Pulmonary Arterial Hypertension by Therapies

15. Market Outlook

15.1. United States Market Size

15.1.1. Total Market Size of Pulmonary Arterial Hypertension in United States

15.1.2. Market Size of Pulmonary Arterial Hypertension by Therapies in United States

15.2. EU-5 Market Size

15.2.1. Germany

15.2.1.1. Total Market size of Pulmonary Arterial Hypertension in Germany

15.2.1.2. Market Size of Pulmonary Arterial Hypertensionby Therapies in Germany

15.2.2. France

15.2.2.1. Total Market size of Pulmonary Arterial Hypertension in France

15.2.2.2. Market Size of Pulmonary Arterial Hypertensionby Therapies in France

15.2.3. Italy

15.2.3.1. Total Market size of Pulmonary Arterial Hypertension in Italy

15.2.3.2. Market Size of Pulmonary Arterial Hypertension by Therapies in Italy

15.2.4. Spain

15.2.4.1. Total Market size of Pulmonary Arterial Hypertension in Spain

15.2.4.2. Market Size of Pulmonary Arterial Hypertension by Therapies in Spain

15.2.5. United Kingdom

15.2.5.1. Total Market size of Pulmonary Arterial Hypertension in United Kindgom

15.2.5.2. Market Size of Pulmonary Arterial Hypertensionby Therapies in United Kingdom

15.3. Japan

15.3.1. Total Market size of Pulmonary Arterial Hypertension in Japan

15.3.2. Market Size of Pulmonary Arterial Hypertension by Therapies in Japan

16. KOL Views

17. Unmet Needs

18. Market Drivers

19. Market Barriers

20. SWOT Analysis

21. Appendix

21.1. Bibliography

21.2. Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

List of Tables:

List of Tables:

Table 1: Summary of Pulmonary Arterial Hypertension, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Organizations contributing towards Pulmonary Arterial Hypertension (PAH)

Table 3: Total Prevalent Patient Population of Pulmonary Arterial Hypertension in 7MM (2018–2030)

Table 4: Total Prevalent Patient Population of Pulmonary Arterial Hypertension in the United States (2018–2030)

Table 5: Sub-type Specific Prevalence of Pulmonary Arterial Hypertension in the United States (2018–2030)

Table 6: Gender specific Prevalence of Pulmonary Arterial Hypertension in United States (2018–2030)

Table 7: Total Prevalent Patient Population of Pulmonary Arterial Hypertension in Germany (2018–2030)

Table 8: Sub-type Specific Prevalence of Pulmonary Arterial Hypertension in Germany (2018–2030)

Table 9: Gender specific Prevalence of Pulmonary Arterial Hypertension in Germany (2018–2030)

Table 10: Total Prevalent Patient Population of Pulmonary Arterial Hypertension in France (2018–2030)

Table 11: Sub-type Specific Prevalence of Pulmonary Arterial Hypertension in France (2018–2030)

Table 12: Gender specific Prevalence of Pulmonary Arterial Hypertension in France (2018–2030)

Table 13: Total Prevalent Patient Population of Pulmonary Arterial Hypertension in Italy (2018–2030)

Table 14: Sub-type Specific Prevalence of Pulmonary Arterial Hypertension in Italy (2018–2030)

Table 15: Gender specific Prevalence of Pulmonary Arterial Hypertension in Italy (2018–2030)

Table 16: Total Prevalent Patient Population of Pulmonary Arterial Hypertension in Spain (2018–2030)

Table 17: Sub-type Specific Prevalence of Pulmonary Arterial Hypertension in Spain (2018–2030)

Table 18: Gender specific Prevalence of Pulmonary Arterial Hypertension in Spain (2018–2030)

Table 19: Total Prevalent Patient Population of Pulmonary Arterial Hypertension in United Kingdom (2018–2030)

Table 20: Sub-type Specific Prevalence of Pulmonary Arterial Hypertension in United Kingdom (2018–2030)

Table 21: Gender specific Prevalence of Pulmonary Arterial Hypertension in United Kingdom (2018–2030)

Table 22: Total Prevalent Patient Population of Pulmonary Arterial Hypertension in Japan (2018–2030)

Table 23: Sub-type Specific Prevalence of Pulmonary Arterial Hypertension in Japan (2018–2030)

Table 24: Gender specific Prevalence of Pulmonary Arterial Hypertension in Japan (2018–2030)

Table 25: Pemziviptadil (PB1046), Clinical Trial Description, 2021

Table 26: Sotatercept, Clinical Trial Description, 2021

Table 27: Ralinepag, Clinical Trial Description, 2021

Table 28: LIQ-861, Clinical Trial Description, 2021

Table 29: Rodatristat Ethyl, Clinical Trial Description, 2021

Table 30: AV-101, Clinical Trial Description, 2021

Table 31: RT234, Clinical Trial Description, 2021

Table 32: GB002, Clinical Trial Description, 2021

Table 33: MK-5475, Clinical Trial Description, 2021

Table 34: Treprostinil Palmitil, Clinical Trial Description, 2021

Table 35: L606, Clinical Trial Description, 2021

Table 36: 7 Major Market Size of Pulmonary Arterial Hypertension in USD Million (2018–2030)

Table 37: 7 Major Market Size of Pulmonary Arterial Hypertension by Therapies in USD Million (2018–2030)

Table 38: United States Market Size of Pulmonary Arterial Hypertension in USD Million (2018–2030)

Table 39: United States Market Size of Pulmonary Arterial Hypertension by Therapies in USD Million (2018–2030)

Table 40: Germany Market Size of Pulmonary Arterial Hypertension in USD Million (2018–2030)

Table 41: Germany Market Size of Pulmonary Arterial Hypertension by Therapies in USD Million (2018–2030)

Table 42: France Market Size of Pulmonary Arterial Hypertension in USD Million (2018–2030)

Table 43: France Market Size of Pulmonary Arterial Hypertension by Therapies in USD Million (2018–2030)

Table 44: Italy Market Size of Pulmonary Arterial Hypertension in USD Million (2018–2030)

Table 45: Italy Market Size of Pulmonary Arterial Hypertension by Therapies in USD Million (2018–2030)

Table 46: Spain Market Size of Pulmonary Arterial Hypertension in USD Million (2018–2030)

Table 47: Spain Market Size of Pulmonary Arterial Hypertension by Therapies in USD Million (2018–2030)

Table 48: United Kingdom Market Size of Pulmonary Arterial Hypertension in USD Million (2018–2030)

Table 49: United Kingdom Market Size of Pulmonary Arterial Hypertension by Therapies in USD Million (2018–2030)

Table 50: Japan Market Size of Pulmonary Arterial Hypertension in USD Million (2018–2030)

Table 51: Japan Market Size of Pulmonary Arterial Hypertension by Therapies in USD Million (2018–2030)

List of Figures:

List of Figures:

Figure 1: Some of the common signs & symptoms of Pulmonary Arterial Hypertension (PAH)

Figure 2: Depiction of a Persistent Epithelial Defect (PED)

Figure 3: Functional Classification of PAH

Figure 4: Risk Factors of Pulmonary Arterial Hypertension

Figure 5: Pathophysiology of Pulmonary Arterial Hypertension (PAH)

Figure 6: Pathophysiology of Pulmonary Arterial Hypertension (PAH)

Figure 7: Diagnosis Algorithm of Pulmonary Arterial Hypertension (PAH)

Figure 8: Treatment Options for Pulmonary Arterial Hypertension (PAH)

Figure 9: Treatment Algorithm of Pulmonary Arterial Hypertension (PAH)

Figure 10: Total Prevalent Population of Pulmonary Arterial Hypertension in 7MM (2018–2030)

Figure 11: Total Prevalent Patient Population of Pulmonary Arterial Hypertension in the United States (2018–2030)

Figure 12: Sub-type Specific Prevalence of Pulmonary Arterial Hypertension in the United States (2018–2030)

Figure 13: Gender specific Prevalence of Pulmonary Arterial Hypertension in United States (2018–2030)

Figure 14: Total Prevalent Patient Population of Pulmonary Arterial Hypertension in Germany (2018–2030)

Figure 15: Sub-type Specific Prevalence of Pulmonary Arterial Hypertension in Germany (2018–2030)

Figure 16: Gender specific Prevalence of Pulmonary Arterial Hypertension in Germany (2018–2030)

Figure 17: Total Prevalent Patient Population of Pulmonary Arterial Hypertension in France (2018–2030)

Figure 18: Sub-type Specific Prevalence of Pulmonary Arterial Hypertension in France (2018–2030)

Figure 19: Gender specific Prevalence of Pulmonary Arterial Hypertension in France (2018–2030)

Figure 20: Total Prevalent Patient Population of Pulmonary Arterial Hypertension in Italy (2018–2030)

Figure 21: Sub-type Specific Prevalence of Pulmonary Arterial Hypertension in Italy (2018–2030)

Figure 22: Gender specific Prevalence of Pulmonary Arterial Hypertension in Italy (2018–2030)

Figure 23: Total Prevalent Patient Population of Pulmonary Arterial Hypertension in Spain (2018–2030)

Figure 24: Sub-type Specific Prevalence of Pulmonary Arterial Hypertension in Spain (2018–2030)

Figure 25: Gender specific Prevalence of Pulmonary Arterial Hypertension in Spain (2018–2030)

Figure 26: Total Prevalent Patient Population of Pulmonary Arterial Hypertension in United Kingdom (2018–2030)

Figure 27: Sub-type Specific Prevalence of Pulmonary Arterial Hypertension in United Kingdom (2018–2030)

Figure 28: Gender specific Prevalence of Pulmonary Arterial Hypertension in United Kingdom (2018–2030)

Figure 29: Total Prevalent Patient Population of Pulmonary Arterial Hypertension in Japan (2018–2030)

Figure 30: Sub-type Specific Prevalence of Pulmonary Arterial Hypertension in Japan (2018–2030)

Figure 31: Gender specific Prevalence of Pulmonary Arterial Hypertension in Japan (2018–2030)

Figure 32: 7 Major Market Size of Pulmonary Arterial Hypertension in USD Million (2018–2030)

Figure 33: 7 Major Market Size of Pulmonary Arterial Hypertension by Therapies in USD Million (2018–2030)

Figure 34: Total Market Size of Pulmonary Arterial Hypertension in the United States, USD Million (2018–2030)

Figure 35: The United States Market Size of Pulmonary Arterial Hypertension by Therapies in USD Million

Figure 36: Total Market Size of Pulmonary Arterial Hypertension in the Germany, USD Million (2018–2030)

Figure 37: The Germany Market Size of Pulmonary Arterial Hypertension by Therapies in USD Million (2018–2030)

Figure 38: Market Size of Pulmonary Arterial Hypertension in the France, USD Million (2018–2030)

Figure 39: The France Market Size of Pulmonary Arterial Hypertension by Therapies in USD Million (2018–2030)

Figure 40: Market Size of Pulmonary Arterial Hypertension in the Italy, USD Million (2018–2030)

Figure 41: The Italy Market Size of Pulmonary Arterial Hypertension by Therapies in USD Million (2018–2030)

Figure 42: Market Size of Pulmonary Arterial Hypertension in the Spain, USD Million (2018–2030)

Figure 43: The Spain Market Size of Pulmonary Arterial Hypertension by Therapies in USD Million

Figure 44: Market Size of Pulmonary Arterial Hypertension in the United Kingdom, USD Million (2018–2030)

Figure 45: The United Kingdom Market Size of Pulmonary Arterial Hypertension by Therapies in USD Million (2018–2030)

Figure 46: Market Size of Pulmonary Arterial Hypertension in the Japan, USD Million (2018–2030)

Figure 47: The Japan Market Size of Pulmonary Arterial Hypertension by Therapies in USD Million (2018–2030)

Tags:

License Type

Offer